Tiew, Pei Yee and Dicker, Alison J. and Keir, Holly R. and Poh, Mau Ern and Pang, Sze Lei and Mac Aogain, Micheal and Chua, Branden Qi Yu and Tan, Jiunn Liang and Xu, Huiying and Koh, Mariko Siyue and Tee, Augustine and Abisheganaden, John Arputhan and Chew, Fook Tim and Miller, Bruce E. and Tal-Singer, Ruth and Chalmers, James D. and Chotirmall, Sanjay H. (2021) A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD. European Respiratory Journal, 57 (3). ISSN 0903-1936, DOI https://doi.org/10.1183/13993003.02050-2020.
Full text not available from this repository.Abstract
Introduction: The chronic obstructive pulmonary disease (COPD) bacteriome associates with disease severity, exacerbations and mortality. While COPD patients are susceptible to fungal sensitisation, the role of the fungal mycobiome remains uncertain. Methods: We report the largest multicentre evaluation of the COPD airway mycobiome to date, including participants from Asia (Singapore and Malaysia) and the UK (Scotland) when stable (n=337) and during exacerbations (n=66) as well as nondiseased (healthy) controls (n=47). Longitudinal mycobiome analysis was performed during and following COPD exacerbations (n=34), and examined in terms of exacerbation frequency, 2-year mortality and occurrence of serum specific IgE (sIgE) against selected fungi. Results: A distinct mycobiome profile is observed in COPD compared with controls as evidenced by increased a-diversity (Shannon index; p<0.00I). Significant airway mycobiome differences, including greater interfungal interaction (by co-occurrence), characterise very frequent COPD exacerbators (three or more exacerbations per year) (permutational multivariate ANOVA; adjusted p<0.001). Longitudinal analyses during exacerbations and following treatment with antibiotics and corticosteroids did not reveal any significant change in airway mycobiome profile. Unsupervised clustering resulted in two clinically distinct COPD groups: one with increased symptoms (COPD Assessment Test score) and Saccharomyces dominance, and another with very frequent exacerbations and higher mortality characterised by Aspergillus, Curvularia and Penicillium with a concomitant increase in serum sIgE levels against the same fungi. During acute exacerbations of COPD, lower fungal diversity associates with higher 2-year mortality. Conclusion: The airway mycobiome in COPD is characterised by specific fungal genera associated with exacerbations and increased mortality.
| Item Type: | Article |
|---|---|
| Funders: | National Medical Research Council, Singapore [Grant No: NMRC/Fellowship/0049/2017 & MOH-000141], Nanyang Technological University [Grant No: NIM/03/2018], GlaxoSmithKline, British Lung Foundation |
| Uncontrolled Keywords: | Corticosteroid Treatment; Respiratory-Tract; Cystic-Fibrosis; Lung Microbiome |
| Subjects: | R Medicine > RC Internal medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms Zaharah Ramly |
| Date Deposited: | 14 Sep 2022 08:16 |
| Last Modified: | 14 Sep 2022 08:16 |
| URI: | http://eprints.um.edu.my/id/eprint/34668 |
Actions (login required)
 |
View Item |
